Zila regulatory update

ZILA's OraScan oral cancer diagnostic received marketing approval in the U.K. The product will be sold by Block Drug Co. Inc.'s Stafford-Miller Ltd. subsidiary (Welwyn Garden City, U.K.), which also has sales rights in Australia and the rest of Europe. The Phoenix company will receive an initial license fee of less than $1 million, plus double-digit royalties. ZILA anticipates a mid-year launch of the product. ...